Chart, page-4231

There's no reason why they can't CR to fund the EMA trial to completion and then take a deal afterwards for a licencing deal. So it doesn't all pivot on this coincidentally timed Serepta CR that keeps getting mentioned.

A CR makes a serious statement to competing DMD pharmas that ANP can hold its own and capable to take the trial to completion, without their support. In doing so, it also puts a hefty premium on any future partnerships or licencing agreements. Best of all, it gives an opportunity for new and current shareholders to load up one last time before the SP truly gets going. Almost like a gift from the MD to the crowd. The raise itself should push the SP higher as holders realise the true meaning and effect that the raise will provide.

Any deals after, will enable ANP to begin other trials, choose the right partnerships, sell rights, licences and later the PRV. So whether Serepta is around or not in the imminent future, it doesn't bother me at all. But at some point, likely in one of their ongoing proof trials, Serepta will want to use ANP's drugs.

Great things ahead.